Similar articles

• [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].

  Saito Y. Saito Y. Yakugaku Zasshi. 2011 Feb;131(2):239-46. doi: 10.1248/yakushi.131.239. Yakugaku Zasshi. 2011. PMID: 21297369 Review. Japanese.
• UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.

  Mani S. Mani S. AAPS PharmSci. 2001;3(3):3. doi: 10.1208/ps0303_commentary2. AAPS PharmSci. 2001. PMID: 11783425 Free PMC article. No abstract available.
• Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.

  Takano M, Kato M, Yoshikawa T, Goto T, Furuya K, Kikuchi Y. Takano M, et al. Int J Clin Oncol. 2010 Apr;15(2):224-5. doi: 10.1007/s10147-010-0024-2. Epub 2010 Feb 24. Int J Clin Oncol. 2010. PMID: 20179984 No abstract available.
• Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.

  Giovannetti E, Tibaldi C, Falcone A, Danesi R, Peters GJ. Giovannetti E, et al. J Clin Oncol. 2010 May 10;28(14):e221-2; author reply e223-5. doi: 10.1200/JCO.2009.27.4928. Epub 2010 Mar 29. J Clin Oncol. 2010. PMID: 20351322 No abstract available.
• Cancer pharmacogenomics: current and future applications.

  Watters JW, McLeod HL. Watters JW, et al. Biochim Biophys Acta. 2003 Mar 17;1603(2):99-111. doi: 10.1016/s0304-419x(03)00003-9. Biochim Biophys Acta. 2003. PMID: 12618310 Review.